Literature DB >> 2544252

The role of morphometry in predicting prognosis in pancreatic islet cell tumors.

B D Kenny1, J M Sloan, P W Hamilton, P C Watt, C F Johnston, K D Buchanan.   

Abstract

Morphometry of 31 pancreatic islet cell tumors was examined to determine the value of this technique in assessing tumor behavior. Patients were followed for a mean period of 5.1 years (range, 1 month-14 years) after diagnosis. Initially 17 localized and nine metastatic tumors were studied. Discriminant analysis was carried out on these cases and identified nuclear/cytoplasmic ratio and number of nuclei/mm2 as the significant discriminatory features. These were combined to derive a classification rule which was capable of correctly identifying localized and metastatic tumors in 92% of cases. The classification rule was applied subsequently to an additional five test cases, all of which were classified successfully. The failure of increased nuclear size and pleomorphism to correlate with malignancy in these tumors was confirmed. Tumors which metastasized had significantly greater gross diameters than localized lesions, but overlap existed. Mitotic counts were not a helpful discriminatory feature. Morphometry may be useful in improving histologic assessment of pancreatic islet cell tumor behavior.

Entities:  

Mesh:

Year:  1989        PMID: 2544252     DOI: 10.1002/1097-0142(19890715)64:2<460::aid-cncr2820640220>3.0.co;2-f

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

Review 1.  How malignant is malignant? A brief review of the microscopic assessment of human neoplasms, and the prediction of whether they will metastasize and kill.

Authors:  I Carr; N Pettigrew
Journal:  Clin Exp Metastasis       Date:  1991 Mar-Apr       Impact factor: 5.150

Review 2.  The functioning side of the pancreas: a review on insulinomas.

Authors:  I Maggio; V Mollica; N Brighi; G Lamberti; L Manuzzi; A D Ricci; D Campana
Journal:  J Endocrinol Invest       Date:  2019-07-31       Impact factor: 4.256

3.  Prognostic factors in patients with endocrine tumours of the duodenopancreatic area.

Authors:  I Madeira; B Terris; M Voss; A Denys; A Sauvanet; J F Flejou; V Vilgrain; J Belghiti; P Bernades; P Ruszniewski
Journal:  Gut       Date:  1998-09       Impact factor: 23.059

4.  Increased expression of CD44v6 in endocrine pancreatic tumours but not in midgut carcinoid tumours.

Authors:  B Terris; J F Fléjou; S Dubois; P Ruszniewski; J Y Scoazec; J Belghiti; F Potet; P Bernades; M Mignon; D Hénin
Journal:  Clin Mol Pathol       Date:  1996-08

5.  Prognostic criteria in nonfunctioning pancreatic endocrine tumours.

Authors:  S La Rosa; F Sessa; C Capella; C Riva; B E Leone; C Klersy; G Rindi; E Solcia
Journal:  Virchows Arch       Date:  1996-12       Impact factor: 4.064

6.  Nucleolar and dispersed nucleolar organiser regions (NORs) in differentiating neoplastic from atypical non-neoplastic lesions of the pancreas.

Authors:  M Sato; H Watanabe; Y Ajioka; Y Noda; Y Sakai
Journal:  Gastroenterol Jpn       Date:  1993-02

Review 7.  Predicting prognosis in gastroentero-pancreatic neuroendocrine tumors: an overview and the value of Ki-67 immunostaining.

Authors:  Mina Jamali; Runjan Chetty
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

8.  Proliferative Activity in Pancreatic Endocrine Tumors: Association with Function, Metastases, and Survival.

Authors:  Martha R. Clarke; Evan E. Baker; Robert J. Weyant; Lisa Hill; Sally E. Carty
Journal:  Endocr Pathol       Date:  1997       Impact factor: 3.943

9.  Proliferation Markers and Their Uses in the Study of Endocrine Tumors.

Authors:  Giuseppe Pelosi; Giuseppe Zamboni
Journal:  Endocr Pathol       Date:  1996       Impact factor: 3.943

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.